glp-1 agonists and pancreatitis New data links for weight loss with higher risk for pancreatitis, GI events GLP-1–Based Therapy for Diabetes: What
Description
While the recent phase 3 trial for orforglipron was specifically for type 2 diabetes and not weight loss, the study found that patients who took the drug lost considerable weight
Liu L, Su X, Quinn WJ, Hui S, Krukenberg K, Frederick DW, et al
JAMA Intern Med 2022;182:513-9.ArticlePubMedPMC 40
Newer GLP-1 receptor agonists and obesity-diabetes
S2CID 13300428
